首页|期刊导航|iLIVER|Treatment for unresectable hepatocellular carcinoma patients:Options and management after complete response

Treatment for unresectable hepatocellular carcinoma patients:Options and management after complete response

Jin-Ming Wang Guo-Gao Qiu Zhi-Dong Liu Jia-Yong Su Da-Long Yang Zhu-Jian Deng Zhi-Cheng Li Jian-Hong Zhong

iLIVER2025，Vol.4Issue(1)：P.52-54,3.

iLIVER2025，Vol.4Issue(1)：P.52-54,3.DOI:10.1016/j.iliver.2025.100145

Treatment for unresectable hepatocellular carcinoma patients:Options and management after complete response

Jin-Ming Wang ¹Guo-Gao Qiu ¹Zhi-Dong Liu ¹Jia-Yong Su ¹Da-Long Yang ¹Zhu-Jian Deng ¹Zhi-Cheng Li ²Jian-Hong Zhong¹

作者信息

1. Department of Hepatobiliary Surgery,Guangxi Medical University Cancer Hospital,Nanning 530021,Guangxi,China
2. Department of General of Surgery,The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530021,Guangxi,China
折叠

摘要

关键词

solid tumours mrecist rather/advanced hepatocellular carcinoma/complete remission/immunotherapy/recist/unresectable hepatocellular carcinoma/mrecist/modified response evaluation criteria

分类

医药卫生

引用本文复制引用

Jin-Ming Wang,Guo-Gao Qiu,Zhi-Dong Liu,Jia-Yong Su,Da-Long Yang,Zhu-Jian Deng,Zhi-Cheng Li,Jian-Hong Zhong..Treatment for unresectable hepatocellular carcinoma patients:Options and management after complete response[J].iLIVER,2025,4(1):P.52-54,3.

基金项目

supported by the Guangxi Key Research and Development Plan(GuiKe AB24010082) （GuiKe AB24010082）

the First-class Discipline Innovation-driven Talent Program of Guangxi Medical University. （）

iLIVER

ISSN：2772-9478

访问量0

下载量0

段落导航